−0.265 EUR
−8.64 M EUR
145.00 K EUR
26.69 M
About CROSSJECT
Sector
Industry
CEO
Patrick Alexandre
Website
Headquarters
Dijon
Founded
2001
ISIN
FR0011716265
FIGI
BBG005YTKZ16
Crossject SA manufactures and markets needle free injection system. It develops and produces generic drugs such as methotrexate, epinephrin, and sumatriptan. The company distributes its products under the Zeneo brand. Crossject was founded by Patrick Alexandre and Xavière Castano on August 8, 2001 and is headquartered in Dijon, France.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of ALCJ is 2.080 EUR — it hasn't changed in the past 24 hours. Watch CROSSJECT stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on EURONEXT exchange CROSSJECT stocks are traded under the ticker ALCJ.
ALCJ stock has risen by 3.00% compared to the previous week, the month change is a −12.90% fall, over the last year CROSSJECT has showed a −52.53% decrease.
We've gathered analysts' opinions on CROSSJECT future price: according to them, ALCJ price has a max estimate of 4.30 EUR and a min estimate of 4.30 EUR. Watch ALCJ chart and read a more detailed CROSSJECT stock forecast: see what analysts think of CROSSJECT and suggest that you do with its stocks.
ALCJ reached its all-time high on Feb 25, 2014 with the price of 12.900 EUR, and its all-time low was 1.005 EUR and was reached on Dec 28, 2018. View more price dynamics on ALCJ chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
ALCJ stock is 2.70% volatile and has beta coefficient of 1.28. Track CROSSJECT stock price on the chart and check out the list of the most volatile stocks — is CROSSJECT there?
Today CROSSJECT has the market capitalization of 84.76 M, it has decreased by −4.28% over the last week.
Yes, you can track CROSSJECT financials in yearly and quarterly reports right on TradingView.
ALCJ net income for the last half-year is −6.40 M EUR, while the previous report showed −4.08 M EUR of net income which accounts for −57.07% change. Track more CROSSJECT financial stats to get the full picture.
No, ALCJ doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 28, 2024, the company has 110.00 employees. See our rating of the largest employees — is CROSSJECT on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. CROSSJECT EBITDA is −9.95 M EUR, and current EBITDA margin is −6.83 K%. See more stats in CROSSJECT financial statements.
Like other stocks, ALCJ shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade CROSSJECT stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So CROSSJECT technincal analysis shows the neutral today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating CROSSJECT stock shows the strong sell signal. See more of CROSSJECT technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.